FACTORS ASSOCIATED WITH PRESCRIBING OF TERIFLUNOMIDE AND DIMETHYL FUMARATE VERSUS FINGOLIMOD IN MULTIPLE SCLEROSIS

被引：0
|
作者：
Earla, J. r [1 ]
Hutton, G. J. [2 ]
Aparasu, R. R. [3 ]
机构：
[1] Univ Houston, Coll Pharm, Fords, NJ USA
[2] Baylor Coll Med, McNair Campus, Houston, TX 77030 USA
[3] Univ Houston, Coll Pharm, Houston, TX 77030 USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HSD13
引用
收藏
页码：S482 / S482
页数：1
相关论文
共 50 条
  • [21] Haematological abnormalities in a series of patients with multiple sclerosis treated with teriflunomide or dimethyl fumarate
    Garcia-Estevez, D. A.
    Sabbagh, N.
    Perez Lorenzo, G.
    Pardo Parrado, M.
    Lopez Diaz, L. M.
    Cid Rodriguez, C.
    Ozaita Arteche, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 915 - 915
  • [22] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
    Mueller, J.
    Schaedelin, S.
    Benkert, P.
    Haenni, P.
    Schmid, J.
    Derfuss, T.
    Kuhle, J.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 676 - 676
  • [23] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
    Muller, Jannis
    Schadelin, Sabine
    Lorscheider, Johannes
    Benkert, Pascal
    Hanni, Peter
    Schmid, Jurg
    Kuhle, Jens
    Derfuss, Tobias
    Granziera, Cristina
    Yaldizli, Ozgur
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (12) : 3809 - 3818
  • [24] Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
    Norborg, H.
    Riise, T.
    Myhr, K. -M.
    Grytten, N.
    Wergeland, S.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 712 - 712
  • [25] Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
    Norborg, Hilde
    Riise, Trond
    Myhr, Kjell-Morten
    Grytten, Nina
    Wergeland, Stig
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (02)
  • [26] Predicting the efficacy of fingolimod versus dimethyl fumarate in patients with multiple sclerosis using a statistical modelling approach
    Bergvall, N.
    Nixon, R.
    Tomic, D.
    Sfikas, N.
    Cutter, G.
    Giovannoni, G.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 519 - 520
  • [27] Effect of teriflunomide versus dimethyl fumarate on cognitive performance in multiple sclerosis patients: real-world data
    Zohar, D. N.
    Achiron, A.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 848 - 849
  • [28] COST-EFFECTIVENESS OF FINGOLIMOD, TERIFLUNOMIDE, DIMETHYL FUMARATE AND INTRAMUSCULAR INTERFERON BETA-1A IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Zhang, X.
    Hay, J. W.
    VALUE IN HEALTH, 2014, 17 (03) : A59 - A60
  • [29] Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: two year experience
    Vollmer, B. L.
    Nair, K. V.
    Sillau, S. H.
    Corboy, J.
    Vollmer, T. L.
    Alvarez, E.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 341 - 341
  • [30] Comparison of Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two Year Experience
    Vollmer, Brandi
    Nair, Kavita
    Sillau, Stefan
    Corboy, John
    Vollmer, Timothy
    Alvarez, Enrique
    NEUROLOGY, 2016, 86
12345